On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune ...

S hares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved its drug Uplizna to reduce the ...

April 3, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with ...

As Amgen waits for an FDA decision on a second indication for its B cell-depleting therapy Uplizna, it has new data suggesting a third may be coming down the pipe. New data from the phase 3 MINT ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Uplizna reduced the risk of IgG4-RD flare by 87%, with 10.3% of patients on Uplizna experiencing a flare versus 59.7% on placebo. 58.8% of Uplizna patients achieved flare-free, corticosteroid-free ...

In rare diseases, Amgen has generally reached a new level after the purchase of Horizon. TEPEZZA, KRYSTEXXA, UPLIZNA and TAVNEOS drugs are growing at a high rate, and there is almost no ...

April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O), opens new tab drug, Uplizna, to help reduce the risk of flares in patients with a rare ...

April 3, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with ...

amgn amgen inc uplizna® (inebilizumab-cdon) ... uplizna® (inebilizumab-cdon) is now the first and only fda-approved treatment for igg4-related disease pr newswire thousand oaks, calif., april ...